ReviewNature reviews. Urology2025
Metastasis development in non-muscle-invasive bladder cancer.
Review in Nature reviews. Urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Before the seeds arrive: pre-metastatic niche orchestration in bladder cancer.Cancer metastasis reviews · 2026Review
- Modification-Selective Inhibition of Succinate Dehydrogenase a Enables Tumor-Restricted Mitochondrial Modulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Natural Products Targeting Acetylation in Bladder Cancer: Mechanistic Basis, Therapeutic Potential, and Future Perspectives.Current issues in molecular biology · 2026Review
- Metastatic non-muscle invasive bladder cancer: histology-specific metastatic patterns and survival in a national cancer database analysis.International urology and nephrology · 2026Article
- Mucoadhesive tumor-penetrating nanomedicine for intravesical chemo-immunotherapy against bladder cancer.Science advances · 2026Article
- Machine learning prediction of postoperative recurrence in bladder cancer using clinical and laboratory indicators.Scientific reports · 2026Article
- Oncosexology: A Narrative Review on Sexual Health and Quality of Life in Cancer Patients.Cancer medicine · 2026Review
- CircBARD1 suppresses tumor progression driven by H3K18 lactylation-CCNA2 axis in human bladder cancer.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Integration of bulk and single-cell transcriptomic sequencing reveals the neutrophil heterogeneity in bladder cancer and establishes a prognostic model.Discover oncology · 2026Article
- DCLK1 drives malignant progression and chemoresistance of bladder cancer by deubiquitinating HDAC6.Molecular cancer · 2026Article
- Clonal evolution and stromal crosstalk drive an invasive epithelial program in bladder cancer.Frontiers in cell and developmental biology · 2026Article
- A prediction model for urological tumor metastasis using liquid biopsy-derived biomarkers.Frontiers in medicine · 2026Article
- Urinary Microbiota Composition in Treatment-Naïve Bladder Cancer: A Case-Control Study with Tumor Invasiveness Stratification.Medicina (Kaunas, Lithuania) · 2025Article
- Catalpol: An Iridoid Glycoside With Potential in Combating Cancer Development and Progression-A Comprehensive Review.Phytotherapy research : PTR · 2025Review
- Pan-Immune-Inflammation Value as a Predictor of Long-Term Outcomes in Patients with Urothelial Carcinoma of the Bladder: A Pilot Study.Current oncology (Toronto, Ont.) · 2025Article
- Prognostic factors in T1 high-grade urothelial carcinoma of the bladder with lymphovascular invasion: a retrospective cohort study.International urology and nephrology · 2025Article
- ɑ1,3-mannosyltransferase promotes the malignant progression of bladder cancer through activating TNF signaling pathway.European journal of medical research · 2025Article
- Mevalonate Metabolic Reprogramming Drives Cisplatin Resistance in Bladder Cancer: Mechanisms and Therapeutic Targeting.Protein and peptide letters · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-muscle-invasive bladder cancer (NMIBC) is the most common type of bladder cancer presentation and is characterized by a varying probability of recurrence and progression. Sporadically, patients with NMIBC might also develop tumour metastases without any pathological evidence of muscle-invasive disease within the bladder, a condition known as metastatic NMIBC. In the published literature, this phenomenon is limited to several case reports and small reviews, with few data regarding the possible aetiologies. Several possible factors can be potentially associated with metastatic NMIBC, including tumour understaging, the number of transurethral resection procedures received by the patient, the presence of circulating tumour cells, the modality used for diagnostic cystoscopy and possible gender-associated differences. In this Perspective, our aim was to integrate and report currently available data on this relatively rare entity and provide some potential aetiological explanations.
Indexed as
Identifiers
39567681What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.